1100 Winter Street
About AMAG Pharmaceuticals
Founded in 1981, AMAG Pharmaceuticals is committed to improving the health outcomes of patients through the development and commercialization of specialty pharmaceutical products.
AMAG currently markets a therapeutic intravenous iron compound for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) and an oral rinse for the management of oral mucositis in the United States. To learn more about our products, click here. Along with driving organic growth of its lead product, AMAG intends to expand its portfolio with additional commercial-stage specialty pharmaceuticals. The company is seeking complementary products that leverage the company's commercial footprint and focus on hematology and oncology centers and hospital infusion centers.
Our iron oxide particles are composed of bioavailable iron that is easily absorbed by the body and incorporated into the body's iron stores. As a result, products using our core technology are well suited for use in intravenous iron replacement therapy.
326 articles with AMAG Pharmaceuticals
It’s a busy week for the U.S. Food and Drug Administration (FDA) with quite a number of pending drug approvals, several of which were delayed for a variety of reasons. Here’s a look.
Shares of AMAG Pharmaceuticals plunged more than 17 percent Friday after the company said its Phase III PROLONG trial of Makena failed to demonstrate a statistically significant difference from placebo in preventing preterm births.
With more than 15 million people in need of anticoagulants around the world, AMAG sees a significant future for ciraparantag.
AMAG Pharmaceuticals and Endoceutics Announce Presentation at the 2018 Annual Meeting of The North American Menopause Society on the Effect of Time Since Menopause, Age and Previous Hormone Therapy on the Response to Intravaginal Prasterone
Study Suggests that While All Postmenopausal Women Benefit from Treatment with Prasterone (INTRAROSA®), Women Experience Greatest Relief of Moderate to Severe Dyspareunia when started on INTRAROSA® within One to Two Years after Menopause
10/1/2018Here's a look at who shook things up in the world of pharma and biotech this week.
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced it has acquired global rights to develop and market digoxin immune Fab (ovine) (DIF), a polyclonal antibody in development for the treatment of severe preeclampsia in pregnant women.
The past few days has had a flurry of activity in the industry with leadership changes. Let's take a look at some of those!
9/4/2018Biopharm companies closed out August with a plethora of changes to executive and senior leadership positions. Let's take a look.
AMAG Pharmaceuticals will secure $530 million in cash as the company divests Cord Blood Registry to GI Partners. Focus will now be on pharmaceutical products.
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for bremelanotide.
There have been a number of leadership changes in biotech companies over the last week. BioSpace has put together a list of new c-suite level hires and position changes.
Makena was approved by the FDA in February 2011 and remains the first and only FDA-approved treatment option currently available for pregnant women who have had a prior spontaneous preterm birth.
AMAG Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application (sNDA) for Feraheme (ferumoxytol injection)
This sNDA approval immediately doubles the number of patients who could benefit from Feraheme to include both CKD and non-CKD patients.
Here is a look at a few important regulatory events scheduled for the month of February.
A live audio webcast of the presentation and following breakout session will be accessible through the Investors section of AMAG’s website.
This is definitely a list few, if any, companies want to be on.
If approved, the auto-injector will join the Makena portfolio, which also includes the FDA-approved intramuscular injection.
AMAG Announces Autologous Cord Blood Cells Improve Motor Function in Some Children With Cerebral Palsy
More than one-third of study participants in Phase 2 Study were Cord Blood Registry (CBR) clients.
This study was comprised of approximately 2,000 adult patients with iron deficiency anemia regardless of the cause who had failed or could not tolerate oral iron therapy
Total GAAP revenue for the third quarter of 2017 increased to $153.7 million, 7% higher than the same period last year.